|1.||Friedman, Henry S: 2 articles (07/2014 - 01/2007)|
|2.||Schneider, Susan M: 1 article (07/2014)|
|3.||Affronti, Mary Lou: 1 article (07/2014)|
|4.||Schlundt, Susan: 1 article (07/2014)|
|5.||Herndon, James E: 1 article (07/2014)|
|6.||Desjardins, Annick: 1 article (01/2014)|
|7.||Gunawardana, Roshaine: 1 article (01/2014)|
|8.||Jallo, George: 1 article (02/2012)|
|9.||Deletis, Vedran: 1 article (02/2012)|
|10.||Perin, Noel: 1 article (02/2012)|
|1.||Brain Neoplasms (Brain Tumor)
01/01/2014 - "Following a 2-year fellowship in neuro-oncology at The Preston Robert Tisch Brain Tumor Center at Duke, she joined the Center as faculty, in July 2005. "
01/01/2014 - "Annick Desjardins, MD, FRCPC, speaks to Roshaine Gunawardana, Managing Commissioning Editor: Annick Desjardins is Associate Professor within the Department of Neurology and is the Director of Clinical Research at The Preston Robert Tisch Brain Tumor Center at Duke. "
09/01/2011 - "Coulter Translational Partners Grant Program, Preston Robert Tisch Brain Tumor Center at Duke, and National Institute of Allergy and Infectious Diseases. "
01/01/2007 - "Using a cross-sectional design, 106 brain tumor patients (age range, 32 to 83 years) who received treatment at the Preston Robert Tisch Brain Tumor Center (BTC) at Duke completed a questionnaire that assessed self-reported exercise behavior, exercise interest and preferences during active and off-treatment periods. "
07/01/2014 - "A review of Duke University Preston Robert Tisch Brain Tumor Center (PRTBTC)'s usual practice demonstrates a high incidence (45%) of CINV, despite premedication with short-acting 5-HT3-serotonin-receptor antagonists (5-HT3-RAs). "
|2.||Spinal Cord Diseases
|3.||Nervous System Diseases (Neurological Disorders)